日本一项实用性、多中心、开放标签、随机、3期、非劣效性试验：用于难治性转移性结直肠癌的14天与28天 trifluridine–tipiracil 联合 bevacizumab 方案比较（PRABITAS）。
完整研究 👉🏼https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901782-4/fulltext
@TheLancet #ESMO26
34 浏览 · 0 赞 · 0 转发 · 0 回复
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase
https://esmocongress.esmo.orgLong-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.orgOutcomes with trifluridine/tipiracil plus bevacizumab across age groups in metastatic colorectal cancer: The BeTAS study
https://esmocongress.esmo.orgBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial
https://esmocongress.esmo.orgFinal overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervic
https://esmocongress.esmo.org来源：Vania Wisdom · x.com